QuidelOrtho Reports Third Quarter 2026 Financial Results
― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ― ― Updated Full-Year 2026 Financial Guidance Narrowing Prior...